*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Kaisa Health Group Holdings Limited**
**佳兆業健康集團控股有限公司**
*(Incorporated in Bermuda with limited liability)*
**(Stock Code: 876)**

# TERMINATION OF MAJOR TRANSACTION AND EXEMPTED CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF FURTHER LIMITED PARTNERSHIP INTERESTS IN THE LIMITED PARTNERSHIP

Reference is made to the announcement (the "**Announcement**") made by Kaisa Health Group Holdings Limited dated 30 April 2025 in relation to, among other things, the proposed acquisition of 3.4904% limited partnership interests in 珠海金鎰銘股權投資基金合夥企業(有限合夥) (Zhuhai Jinyiming Equity Investment Fund Partnership (L.P.))*. Unless the context otherwise requires, capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

The Board announces that since the conditions precedent set out in the Transfer Agreement have not been satisfied in full before the longstop date (being 60 days after the date of the Transfer Agreement) and the parties, after further negotiations, have not agreed to a further extension of the longstop date, on 23 July 2025, the Purchaser, the Vendor and the General Partner mutually agreed to terminate the Transfer Agreement with effect from on 23 July 2025. Accordingly, the Acquisition will not proceed.

The Board considers that the termination of the Transfer Agreement will not have any material adverse impact on the financial position and operation of the Group.

By order of the Board
**Kaisa Health Group Holdings Limited**
**Kwok Ying Shing**
*Chairman*

Hong Kong, 23 July 2025

*As at the date of this announcement, the Board comprises Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Mr. Liu Lihao, Ms. Luo Tingting, Mr. Xie Binhong and Mr. Ye Haoda as executive Directors; and Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying as independent non-executive Director.*